Daily Stock Analysis, EARS, Auris Medical Holding AG, priceseries

Auris Medical Holding AG. Daily Stock Analysis
Stock Information
Open
2.02
Close
1.91
High
2.02
Low
1.85
Previous Close
2.02
Daily Price Gain
-0.11
YTD High
10.90
YTD High Date
Jan 15, 2019
YTD Low
1.85
YTD Low Date
Oct 15, 2019
YTD Price Change
-7.17
YTD Gain
-78.96%
52 Week High
37.40
52 Week High Date
Oct 16, 2018
52 Week Low
1.85
52 Week Low Date
Oct 15, 2019
52 Week Price Change
-27.69
52 Week Gain
-93.55%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 10. 2017
7.80
Mar 27. 2017
8.77
11 Trading Days
12.45%
Link
LONG
Sep 28. 2017
7.99
Oct 12. 2017
8.66
10 Trading Days
8.44%
Link
LONG
Aug 16. 2018
4.80
Sep 5. 2018
5.44
13 Trading Days
13.37%
Link
LONG
Oct 5. 2018
9.40
Oct 10. 2018
10.04
3 Trading Days
6.86%
Link
LONG
Oct 11. 2018
13.60
Oct 18. 2018
17.60
5 Trading Days
29.41%
Link
LONG
Dec 28. 2018
9.72
Dec 31. 2018
10.27
1 Trading Days
5.66%
Link
LONG
May 8. 2019
5.37
May 9. 2019
5.79
1 Trading Days
7.73%
Link
Company Information
Stock Symbol
EARS
Exchange
NasdaqGM
Company URL
http://www.aurismedical.com
Company Phone
41 (0)61 201 13 50
CEO
Thomas Meyer
Headquarters
-
Business Address
FALKNERSTRASSE 4, 4001 BASEL, SWITZERLAND 00000
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001601936
About

Auris Medical Holding AG engages in the research, development, and commercialization of pharmaceutical products for inner ear disorders. Its product portfolio targets to treat tinnitus, Menière's disease, and hearing loss. The company was founded by Thomas Meyer on April 1, 1998 and is headquartered in Zug, Switzerland.

Description

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.